Glycomine: $115 Million (Series C) Raised To Advance GLM101 Drug Candidate
By Amit Chowdhry ● Apr 21, 2025
Glycomine - a biotechnology company focused on developing transformative new therapies for orphan diseases - announced a $115 million Series C financing to advance its lead candidate GLM101, into a Phase 2b clinical trial. This funding was led by CTI Life Sciences Fund, funds managed by abrdn, and Advent Life Sciences, along with continued investment from existing investors, Novo Holdings, Sanofi Ventures, Abingworth, RiverVest Venture Partners, Sanderling Ventures, Chiesi Ventures, Remiges Ventures, and Asahi Kasei Ventures.